Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Gemtesa (vibegron) is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Reduction in Incontinence: Vibegron demonstrated a significantly greater reduction in total urinary incontinence episodes compared to mirabegron and tolterodine over 52 weeks.
• Mean Voided Volume/Micturition: Vibegron was more effective than mirabegron in increasing mean voided volume per micturition, with significantly greater improvements noted at 12 and 52 weeks.
• Comparative Effectiveness: Solifenacin 10 mg was the most effective in reducing mean daily micturitions and incontinence episodes, while fesoterodine 8 mg and oxybutynin 5 mg showed superior outcomes in reducing urgency incontinence episodes and increasing voided volume/micturition, respectively.
• Both vibegron and mirabegron demonstrated safety profiles similar to placebo, with the exception that mirabegron was associated with a higher incidence of nasopharyngitis and cardiovascular adverse events.
• Common adverse events reported for vibegron and mirabegron included hypertension, urinary tract infection, headache, and nasopharyngitis. Vibegron specifically showed a significantly increased incidence of hypertension compared to placebo.